Clinical Trial Update: Neoadjuvant Fluzoparib Combined With Camrelizumab in Germline BRCA-mutated HER2-negative Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating neoadjuvant fluzoparib with camrelizumab in germline BRCA-mutated, HER2-negative breast cancer is currently enrolling by invitation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Germline Brca-mutated Breast Cancer

Drugs mentioned

• Camrelizumab (camrelizumab)
• Fluzoparib (fluzoparib)

Snippet

Sponsor: Peking University People's Hospital | Conditions: Germline BRCA-mutated HER2-negative Breast Cancer | Phase 2 | Status: ENROLLING_BY_INVITATION